| Literature DB >> 24515930 |
Stuart Keeble1, Gary A Abel, Catherine L Saunders, Sean McPhail, Fiona M Walter, Richard D Neal, Gregory P Rubin, Georgios Lyratzopoulos.
Abstract
Cancer awareness public campaigns aim to shorten the interval between symptom onset and presentation to a doctor (the 'patient interval'). Appreciating variation in promptness of presentation can help to better target awareness campaigns. We explored variation in patient intervals recorded in consultations with general practitioners among 10,297 English patients subsequently diagnosed with one of 18 cancers (bladder, brain, breast, colorectal, endometrial, leukaemia, lung, lymphoma, melanoma, multiple myeloma, oesophageal, oro-pharyngeal, ovarian, pancreatic, prostate, renal, stomach, and unknown primary) using data from of the National Audit of Cancer Diagnosis in Primary Care (2009-2010). Proportions of patients with 'prompt'/'non-prompt' presentation (0-14 or 15+ days from symptom onset, respectively) were described and respective odds ratios were calculated by multivariable logistic regression. The overall median recorded patient interval was 10 days (IQR 0-38). Of all patients, 56% presented promptly. Prompt presentation was more frequent among older or housebound patients (p < 0.001). Prompt presentation was most frequent for bladder and renal cancer (74% and 70%, respectively); and least frequent for oro-pharyngeal and oesophageal cancer (34% and 39%, respectively, p <.001). Using lung cancer as reference, the adjusted odds ratios of non-prompt presentation were 2.26 (95% confidence interval 1.57-3.25) and 0.42 (0.34-0.52) for oro-pharyngeal and bladder cancer, respectively. Sensitivity analyses produced similar findings. Routinely recorded patient interval data reveal considerable variation in the promptness of presentation. These findings can help to prioritise public awareness initiatives and research focusing on symptoms of cancers associated with greater risk of non-prompt presentation, such as oro-pharyngeal and oesophageal cancer.Entities:
Keywords: bladder; cancer; delay; oesophageal; oro-pharyngeal; patient interval; presentation; promptness; renal; variation
Mesh:
Year: 2014 PMID: 24515930 PMCID: PMC4277322 DOI: 10.1002/ijc.28763
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396
Principal advantages and limitations of the two main approaches to measuring the patient interval
| Strengths | Limitations | |
|---|---|---|
| Patient interview (or questionnaire) studies | ||
| Studies of medical consultation records |
Figure 1Derivation of the analysis sample. Percentage values relate to the initial sample of 14,320 patients with one of the 18 studied cancers.
Sample characteristics and descriptive statistics for patient interval by patient characteristic and cancer (n = 10,297)
| Patient interval binary category | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient interval (days) | Prompt (0–14 days) | Non-prompt (15+ days) | ||||||||||
| 25th Centile | Median | 75th Centile | 90th Centile | 95th Centile | % | % | ||||||
| 15–44 | 784 | 1 | 13 | 42 | 120 | 242 | 439 | 56.0 | 345 | 44.0 | ||
| 45–54 | 1,220 | 1 | 14 | 45 | 108 | 187 | 649 | 53.2 | 571 | 46.8 | ||
| 55–64 | 2,170 | 0 | 12 | 41 | 102 | 191 | 1,186 | 54.7 | 984 | 45.3 | ||
| 65–74 | 2,807 | 0 | 11 | 43 | 112 | 185 | 1,526 | 54.4 | 1,281 | 45.6 | ||
| 75–84 | 2,459 | 0 | 7 | 31 | 92 | 183 | 1,463 | 59.5 | 996 | 40.5 | ||
| 85+ | 857 | 0 | 7 | 31 | 95 | 188 | 526 | 61.4 | 331 | 38.6 | ||
| Male | 5,028 | 0 | 11 | 43 | 116 | 200 | 2,742 | 54.5 | 2,286 | 45.5 | ||
| Female | 5,269 | 0 | 10 | 33 | 92 | 182 | 3,047 | 57.8 | 2,222 | 42.2 | ||
| Bladder | 601 | 0 | 2 | 16 | 67 | 141 | 446 | 74.2 | 155 | 25.8 | ||
| Renal | 209 | 0 | 3 | 19 | 74 | 184 | 146 | 69.9 | 63 | 30.1 | ||
| Brain | 125 | 1 | 7 | 26 | 96 | 154 | 81 | 64.8 | 44 | 35.2 | ||
| Breast | 2,124 | 1 | 7 | 27 | 77 | 164 | 1371 | 64.5 | 753 | 35.5 | ||
| Unknown primary | 110 | 0 | 7 | 23 | 64.5 | 104 | 69 | 62.7 | 41 | 37.3 | ||
| Leukaemia | 239 | 0 | 7 | 30 | 86 | 140 | 144 | 60.3 | 95 | 39.7 | ||
| Prostate | 1,386 | 0 | 6 | 42 | 151 | 283 | 813 | 58.7 | 573 | 41.3 | ||
| Pancreatic | 272 | 1 | 9.5 | 31 | 73 | 97 | 162 | 59.6 | 110 | 40.4 | ||
| Stomach | 187 | 0 | 9 | 33 | 125 | 205 | 104 | 55.6 | 83 | 44.4 | ||
| Lung | 1,126 | 0 | 12 | 33 | 87 | 138 | 622 | 55.2 | 504 | 44.8 | ||
| Myeloma | 127 | 0 | 14 | 40 | 95 | 193 | 69 | 54.3 | 58 | 45.7 | ||
| Endometrial | 311 | 1 | 14 | 57 | 152 | 259 | 165 | 53.1 | 146 | 46.9 | ||
| Ovarian | 270 | 2 | 14 | 51 | 113.5 | 172 | 144 | 53.3 | 126 | 46.7 | ||
| Lymphoma | 482 | 1 | 14 | 43 | 92 | 183 | 243 | 50.4 | 239 | 49.6 | ||
| Melanoma | 477 | 0 | 20 | 69 | 241 | 366 | 216 | 45.3 | 261 | 54.7 | ||
| Colorectal | 1,697 | 1 | 19 | 60 | 131 | 203 | 786 | 46.3 | 911 | 53.7 | ||
| Oesophageal | 407 | 7 | 22 | 46 | 99 | 152 | 158 | 38.8 | 249 | 61.2 | ||
| Oro-pharyngeal | 147 | 7 | 30 | 62 | 122 | 212 | 50 | 34.0 | 97 | 66.0 | ||
| No | 9,707 | 0 | 11 | 39 | 103 | 188 | 5399 | 55.6 | 4308 | 44.4 | ||
| Yes | 590 | 0 | 5 | 28 | 91 | 200 | 390 | 66.1 | 200 | 33.9 | ||
| Total | 10,297 | 0 | 10 | 38 | 103 | 189 | 5,789 | 56.2 | 4,508 | 43.8 | ||
Kruskal–Wallis test.
Chi-squared test.
Proportion of patients with non-prompt presentation and respective unadjusted and adjusted odds ratios (n = 10,297)
| % Non-prompt (15+ days) presentation | Unadjusted odds ratios for non-prompt (15+ days) presentation | Adjusted odds ratios for non-prompt presentation (15+ days) by patient characteristic and cancer diagnosis | |||
|---|---|---|---|---|---|
| 15–44 ( | 44.0 | 0.94 (0.80–1.10) | 0.99 (0.84–1.17) | ||
| 45–54 ( | 46.8 | 1.05 (0.92–1.20) | 1.12 (0.98–1.30) | ||
| 55–64 ( | 45.3 | 0.99 (0.88–1.11) | 0.98 (0.87–1.10) | ||
| 65–74 ( | 45.6 | Baseline | Baseline | ||
| 75–84 ( | 40.5 | 0.81 (0.73–0.90) | 0.83 (0.74–0.93) | ||
| 85+ ( | 38.6 | 0.75 (0.64–0.88) | 0.83 (0.70–0.98) | ||
| Male ( | 45.5 | Baseline | Baseline | ||
| Female ( | 42.2 | 0.87 (0.81–0.95) | 0.93 (0.84–1.03) | ||
| Bladder ( | 25.8 | 0.43 (0.35–0.53) | 0.42 (0.34–0.52) | ||
| Renal ( | 30.1 | 0.53 (0.39–0.73) | 0.51 (0.37–0.71) | ||
| Brain ( | 35.2 | 0.67 (0.46–0.99) | 0.66 (0.45–0.98) | ||
| Breast ( | 35.5 | 0.68 (0.58–0.79) | 0.67 (0.57–0.78) | ||
| Unknown primary ( | 37.3 | 0.73 (0.49–1.10) | 0.75 (0.50–1.12) | ||
| Leukaemia ( | 39.7 | 0.81 (0.61–1.08) | 0.78 (0.58–1.03) | ||
| Prostate ( | 41.3 | 0.87 (0.74–1.02) | 0.83 (0.70–0.98) | ||
| Pancreatic ( | 40.4 | 0.84 (0.64–1.10) | 0.85 (0.65–1.11) | ||
| Stomach ( | 44.4 | 0.98 (0.72–1.34) | 0.99 (0.73–1.35) | ||
| Lung ( | 44.8 | Baseline | Baseline | ||
| Myeloma ( | 45.7 | 1.04 (0.72–1.50) | 1.01 (0.70–1.47) | ||
| Endometrial ( | 46.9 | 1.09 (0.85–1.40) | 1.08 (0.84–1.40) | ||
| Ovarian ( | 46.7 | 1.08 (0.83–1.41) | 1.09 (0.83–1.43) | ||
| Lymphoma ( | 49.6 | 1.21 (0.98–1.50) | 1.15 (0.93 - 1.43) | ||
| Melanoma ( | 54.7 | 1.49 (1.20–1.85) | 1.41 (1.13–1.75) | ||
| Colorectal ( | 53.7 | 1.43 (1.23–1.66) | 1.43 (1.23–1.67) | ||
| Oesophageal ( | 61.2 | 1.94 (1.54–2.45) | 1.94 (1.54–2.45) | ||
| Oropharynheal ( | 66.0 | 2.39 (1.67–3.43) | 2.26 (1.57–3.25) | ||
| No ( | 44.4 | Baseline | Baseline | ||
| Yes ( | 33.9 | 0.64 (0.54–0.77) | 0.67 (0.56–0.81) | ||
This column repeats information presented in Table2, for ease of reference regarding crude proportions.
Figure 2Multivariable logistic regression outputs (adjusted odds ratios and 95% confidence intervals) for non-prompt presentation by sociodemographic characteristic (n = 10,297).
Figure 3Multivariable logistic regression outputs (adjusted odds ratios and 95% confidence intervals) for non-prompt presentation by cancer diagnosis (n = 10,297).